Why is Remus Pharma. falling/rising?

As of 24-Sep, Remus Pharmaceuticals Ltd is currently priced at 789.45, reflecting an increase of 3.55 or 0.45%. Despite this slight uptick, the stock has been underperforming in the longer term, with a year-to-date decline of 36.78% and a one-year drop of 41.24%. Today's performance summary indicates that the stock hit a new 52-week low of Rs. 765.65 earlier in the day. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. Furthermore, there has been a significant decrease in investor participation, with delivery volume falling by 30.11% compared to the 5-day average, which may indicate waning interest among investors.
In the broader market context, Remus Pharmaceuticals has experienced a 1-week return of -2.69%, which is notably worse than the benchmark Sensex's decline of only 1.08%. Over the past month, while the stock has dropped by 16.23%, the Sensex has managed a modest gain of 0.75%. This stark contrast highlights the stock's struggles relative to the overall market. The lack of available positive or negative factors further complicates the assessment of the stock's recent movements, as there are no specific catalysts identified that could explain the current price dynamics.